Peer-reviewed article
Acceptance of the respiratory syncytial virus infant monoclonal antibody nirsevimab among post-partum women in Italy.
Silvia Angelillo, Grazia Miraglia Del Giudice, Giorgia Della Polla, Italo Francesco Angelillo ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001A survey of 476 post-partum women in Italy examined acceptance of nirsevimab, a monoclonal antibody to protect newborns from respiratory syncytial virus (RSV). About half of mothers found the antibody very useful for protecting newborns, and 86.5% had their infant immunized against RSV. Mothers who trusted vaccination information and did not rely on internet or social media for health information were more likely to accept the immunization.
Key points
- 50.8% of post-partum women reported the RSV monoclonal antibody was very useful for newborn protection
- 86.5% of women had their newborn immunized against RSV
- Trust in vaccination information and avoiding internet/social media as information sources were associated with higher acceptance
- Women who had received at least one vaccination during pregnancy were more likely to immunize their child against RSV
- The survey had a high response rate of 96.6%
Limitations
This is a cross-sectional survey measuring attitudes and self-reported behaviors at one point in time, so it cannot determine causation or track acceptance changes over time. The study was conducted only in Southern Italy and may not represent acceptance patterns across the entire country or in other regions.
Abstract
The purposes of the cross-sectional survey were to investigate among a sample of post-partum women in Italy the attitudes and the behaviors about the respiratory syncytial virus (RSV) infant monoclonal antibody and to explore any associations with different characteristics.The survey was conducted between March and April 2025 in teaching and public hospitals randomly selected in Southern Italy. The data were collected using a structured questionnaire through a face-to-face interview for those women in the maternity wards and by telephone for those who were at home.A total of 476 women completed the interview for a response rate of 96.6%. Half (50.8%) reported that the monoclonal antibody was very useful for the protection of the newborn, and this was more likely among mothers who trusted the information they received about vaccinations and those who had not received information from Internet or social media. A total of 86.5% had immunized their newborn against RSV. Women who had received at least one vaccination when pregnant, those who believed that the monoclonal antibody was very useful, those who did not acquire information from Internet or social media, and those who trusted the vaccination information acquired were more likely to have immunized their child.Education and communication strategies must be embedded in pre-natal and maternal health programs, and healthcare workers must be encouraged to actively inform and counsel every new cohort of pregnant women about the role of the RSV immunization to protect their children.
Findings the Hub has extracted
Each claim below is labelled by its type of design and links back to this report.
- Intervention
- Provision of nirsevimab, a respiratory syncytial virus infant monoclonal antibody, to newborns during infancy
- Population
- Post-partum women (n=476) in Southern Italian teaching and public hospitals, March-April 2025
Key finding
86.5% of mothers had their newborn immunized against RSV
Angelillo et al. · PubMed (US National Library of Medicine) · 10 Jun 2026